AEMD..worth a look over
In our quest to innovate life-saving therapeutics, we have persevered through untold challenges to create a single medical device that offers to optimize the benefit of cancer and infectious disease therapies. As our endeavors transitioned beyond R&D, we thought we were cognizant of the entire alphabet soup of healthcare and financial regulatory agencies we would need to navigate to bring our technology to market.
However, on September 30th 2011, we were blindsided by an action never anticipated. The Depository Trust Company (DTC) eliminated the electronic transfer of our securities, otherwise known as a "DTC Chill." As a result, broker-dealers across America began to restrict or prohibit trading in Aethlon Medical shares, which in turn reduced liquidity and inhibited the true sentiment for our company to be accurately reflected by the public markets. A recently published viewpoint of a securities law firm provides a more succinct perspective on a DTC Chill:
"The Depository Trust Company is the only stock depository in the U.S. When DTC provides services as the depository for an issuer's securities, its securities can trade electronically. Without DTC eligibility, it is almost impossible for an issuer to establish an active market in its securities."
As the result of protracted legal effort, DTC has agreed to lift the restriction on the electronic transfer of our securities, which we reported in an SEC filing on January 7th. In a related event, I am pleased to inform shareholders and other interested parties that our transfer agent has notified us that the CUSIP underlying our shares is now unlocked to again allow for our shares to be electronically traded on the DTC system. Thus, signaling the end of a lengthy and disheartening challenge faced by our organization.
While we cannot measure the full impact the DTC Chill, I ask you to consider some of our milestone achievements since September 30th, 2011. Milestone achievements that many biotechnology or medical device organizations would envy.
On the day (yes, the exact same day) the DTC Chill went into effect, we transitioned from a development-stage to revenue-stage organization as the result of a $6.8 Department of Defense (DOD) contract award from the Defense Advanced Research Projects Agency (DARPA). Since contract initiation, we have generated in excess of $2 million in revenues and have advanced the development of a device and blood processing system to combat sepsis.
Related to our DARPA program, we teamed with two larger industry organizations to respond to a $25 million systems integrator contract opportunity. The recipient of this contract has not yet been announced by DARPA.
We reported our first Hepatitis-C (HCV) efficacy data related to the use of our Hemopurifier® as an adjunct to optimize the benefit of standard of care drug therapy. The results exceeded expectations as a three-treatment Hemopurifier® protocol was demonstrated to reduce viral load to undetectable levels in as little as seven days. Since September 30th, 2011, organizations with clinical stage adjunct therapies have been acquired for a much as $11 Billion.
Based on prior discussions with the U.S. Food and Drug Administration (FDA), we established a protocol to elute the post-treatment biological fluid from the Hemopurifier® as a means to quantify HCV capture. The result established an unprecedented data point validating the capture of up to 300 billion copies of HCV during a single treatment. I plan to detail the relevance of this datapoint in a future CEO note.
As the result of our HCV treatment outcomes, the Medanta Medicity Institute is now offering Hemopurifier® therapy on a compassionate-use basis to HCV-infected individuals.
We submitted an Investigational Device Exemption (IDE) to the FDA to request permission to initiate a clinical feasibility study HCV infected individuals who would be enrolled to receive Hemopurifier® therapy. We have since received comments and study design considerations back from FDA and are preparing a response that we hope will lead to the initiation of U.S. clinical studies.
Since September 30th, 2011, we advanced studies that validated the ability of our Hemopurifier® to capture exosomes underlying different forms of cancer. Tumor-secreted exosomes have been discovered to play a vital role in cancer progression and it has recently become clear that a successful war against cancer will need to address these particles. Our Hemopurifier® is the first therapeutic candidate to address tumor-secreted exosomes.
We expanded our intellectual property portfolio of pending and issued patents. As the result of our early exosome research, we were recently issued a patent that protects our cancer treatment strategy in the United States for the next two decades.
We disclosed that researchers at the Morehouse School of Medicine discovered that the Hemopurifier® captures HIV exosomes, which transport NEF protein to assist HIV in maintaining the suppression of the immune system, even when antiviral drugs are able to achieve undetectable viral load in treated patients.
We began shipping our exosome assay (ELLSA), which we originally created to support our own research, to researchers who are utilizing its capabilities to create new diagnostic tools that have the potential to identify a variety of disease conditions in blood and urine.
We received the support of highly regarded thought leaders from the extracorporeal, sepsis, and cancer field who agreed to join our science advisory board.
We believe that these selected achievements portray a company that is making significant progress despite the challenges of being a small public company that was saddled with a DTC Chill since September 30th, 2011.
In closing, I am forever grateful to those shareholders that have loyally supported our endeavors even in the darkest moments. Your belief validates many sacrifices and inspires the strength to continue waging every fight necessary to ensure our innovation has the opportunity to save lives.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
About The Aethlon Hemopurifier®
The Aethlon Hemopurifier® is a first-in-class medical device that selectively targets the rapid clearance of infectious viral pathogens and immunosuppressive proteins from the entire circulatory system. In the treatment of Hepatitis C virus (HCV), human studies have demonstrated that Hemopurifier® therapy may improve immediate, rapid and sustained virologic response rates when administered in the first few days of standard-of-care drug therapy. In addition to accelerating viral load depletion, post-treatment analysis of the Hemopurifier® has documented the capture of up to 300 billion HCV copies of HCV during a single six-hour treatment. Access to Hemopurifier® therapy is available on a compassionate-use basis through the Medanta Medicity Institute (Medicity), a leading center for medical tourism in India. The Medicity is offering treatment access to infected individuals who previously failed or subsequently relapsed standard-of-care drug regimens. The Hemopurifier® is also being offered as a salvage therapy to infected individuals who suffer a viral breakthrough during standard-of-care therapy. U.S. studies of the Hemopurifier® are currently pending approval of an IDE submitted to FDA.
Posted On: 02/06/2013 3:51:04 AM
Post# of 35143
(0)
(0)
Top 10 Most Recent Blog Posts
Small-Cap Stocks and Dow Outperform Amid Market Rebound
Category: Stocks Total Views: 207
By : Addison Perry Updated: 07-25-2024
Wall Street Indexes Rebound on Strong GDP Data
Thursday's main indexes on Wall Street climbed in response to better than expected GDP data. While the Dow and small-cap stocks lagged, the Nasdaq and S&P corrected early losses. After the tech mauling of the last session, this rise brought relief. On route to recoup Wednesday's losses, the Russell 2000 jumped 2%. Investors questioned whether the recent turn to underperformance made sense. Most megacap stocks were set to prolong losse... Continue Reading
Magnificent Seven Stocks Hit Hard by Earnings Reports
Category: Stocks Total Views: 149
By : Lucas Young Updated: 07-25-2024
Tech Giants' Earnings Disappoint, Sparking Market Selloff
Significant market selloff was started by Tesla and Alphabet's latest earnings releases. Investors worried about Tesla's lowest quarterly profit margin in five years. Anxiety about growing AI infrastructure costs and YouTube competition eclipsed Alphabet's better-than-expected earnings. With a tech-heavy Nasdaq Composite falling 3.6%, its worst day since October 2022. The S&P 500 likewise slumped 2.3%. This response... Continue Reading
SK Hynix Reports Record Profit Driven by AI Chip Demand
Category: Stocks Total Views: 160
By : Evelyn Baker Updated: 07-25-2024
SK Hynix Reports Highest Quarterly Profit Since 2018
SK Hynix declared its highest quarterly profit since 2018. For the quarter April–June, the company declared an operating profit of 5.47 trillion won. From the loss of 2.9 trillion won a year before, this is a notable increase. The profit lines up with LSEG SmartEstimate's projections. Analyzes projected a good performance from SK Hynix. Three straight profitable quarters have come from the company. This represents a notable comeba... Continue Reading
June New Home Sales Drop Despite Easing Mortgage Rates
Category: Real Estate Total Views: 138
By : Owen Jenkins Updated: 07-25-2024
New Home Sales Drop to Seven-Month Low in June
June's sales of newly built single-family homes dropped to a seven-month low. With a 0.6% drop noted by the Census Bureau of the Commerce Department, the seasonally adjusted annual rate comes to 617,000 units. Since November, this represents the lowest level. May's sales pace, on the other hand, was raised from the earlier stated 619,000 units to 621,000 units. This surprising decline in June sales is unambiguous evidence that the recover... Continue Reading
Lineage Raises $4.45B in Historic IPO, Valued at $18B
Category: Stocks Total Views: 145
By : Logan Wright Updated: 07-25-2024
Lineage Achieves Historic IPO with $4.45 Billion Raise
With its U.S. initial public offering, Lineage, the biggest cold-storage warehouse operator in the world, raised $4.45 billion. This is the largest worldwide stock market debut of this year. Pricing almost 57 million shares at $78 apiece comprised the IPO. At the top of its stated range, $70 to $82, this price was The company first intended to offer 47 million shares. Still, great demand resulted in the sale of extra shares. The IPO value... Continue Reading
Private Sector Employment Rises Despite Slower Momentum
Category: Economy Total Views: 292
By : Dylan Bailey Updated: 07-24-2024
U.S. Business Activity Hits 27-Month High in July
July's 27-month high in U.S. business activity suggests strong economic momentum. Rising from 54.8 in June to 55.0, the flash U.S. Composite PMI Output Index from S&P Global Since April 2022 this is the highest level. Tracking both manufacturing and services, the index has a reading above 50 suggesting growth. Driven by notable increases in the services sector, this consistent increase points to robust private sector expansion. The ris... Continue Reading
How to Protect Your Rental Real Estate Investment
Category: Real Estate Total Views: 301
By : Olivia Taylor Updated: 07-24-2024
Introduction to Protecting Your Rental Real Estate Investment
Renting real estate has become a go-to investment strategy these days. It's a good way to earn a consistent income and accumulate long-term wealth.
However, renting a real estate property comes with many risks. Your tenant can file a lawsuit against you, property damage risk and unforeseen circumstances can all spoil your investment success.
Therefore, be proactive in protecting your assets, and ensure a wise rental real ... Continue Reading
Weak Summer Demand, China Slowdown Hit Oil Markets
Category: Markets Total Views: 268
By : Thomas Cooper Updated: 07-24-2024
Oil Prices Edge Higher Amid Canadian Wildfires and Falling U.S. Crude Inventories
Though they stayed close to their six-week low, oil prices slightly rose on Wednesday. Prices started to rise following three consecutive sessions of drop. Falling U.S. crude inventories and supply concerns from Canadian wildfires were mostly responsible for this. September Brent crude futures climbed 66 cents to $81.67 a barrel. September U.S. West Texas Intermediate (WTI) crude rose by 78 cents to $77.74 per b... Continue Reading
Tax Disputes and Litigation: Strategies for Effective Resolution
Category: Personal Finance Total Views: 286
By : Kelly Martin Updated: 07-24-2024
Introduction to Managing and Resolving Tax Disputes
Tax disputes are an unavoidable aspect of business that can arise at any time and involve complex legal and financial issues. Whether it's a dispute over tax returns, audit findings, or tax assessments, the potential implications for a business can be significant, affecting not just financial stability but also the reputation of the company. Preparing effectively can make a substantial difference in the resolution process.
Preparing f... Continue Reading
3 Avoidable Marketing Mistakes Real Estate Startups Can Make
Category: Real Estate Total Views: 287
By : Ryan Hughes Updated: 07-24-2024
Introduction to Effective Marketing Strategies for Real Estate Startups
Starting a business is no easy feat. There’s less comfort in knowing that 90% of startups fail, according to 2024 data sourced from Exploding Topics. The same report found that new business success rates are 10 to 20% over the long term.
The odds against the real estate sector didn’t bode well. About 48% of real estate startups failed within four years. However, there’s still hope for aspiring entrepr... Continue Reading